No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
LAMR240719C100000
- 20.73
- 0.000.00%
15min DelayClose Jun 12 11:27 ET
0.00High0.00Low
0.00Open20.73Pre Close0 Volume0 Open Interest100.00Strike Price0.00Turnover1055.60%IV-0.46%PremiumJul 19, 2024Expiry Date21.29Intrinsic Value100Multiplier-2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9621Delta0.0065Gamma5.85Leverage Ratio-13.6082Theta0.0001Rho5.63Eff Leverage0.0010Vega
Intraday
- 5D
- Daily
News
TD Cowen Says Lamar to Maintain Its Top Spot in Billboard Market, Starts With Buy
Express News | Lamar Advertising Shares up 1.1% After TD Cowen Initiates Coverage With Buy Rating
TD Cowen Initiates Lamar Advertising Co(LAMR.US) With Buy Rating, Announces Target Price $135
TD Cowen analyst Lance Vitanza initiates coverage on $Lamar Advertising Co(LAMR.US)$ with a buy rating, and sets the target price at $135.According to TipRanks data, the analyst has a success rate
Express News | Lamar Advertising Co : TD Cowen Initiates Coverage With Buy Rating; Target Price $135
Express News | Citigroup Downgrades Lamar Advertising to Neutral, Announces $122 Price Target
Lamar Advertising Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 4.41% Citigroup → $122 Downgrades Buy → Neutral 02/26/2024 -5.86% Morgan Stanley $105 → $110
Comments
Upgrades
• $Allegiance(ABTX.US$ : Raymond James Upgrades to Outperform from Market Perform - PT $43
• $Bunge(BG.US$: JPMorgan Upgrades to Overweight from Neutral - PT $106 (from $130)
• $Cerence(CRNC.US$ : RBC Capital Upgrades to Sector Perform from Underperform - PT $27 (from $28)
• $First Mid Bancshares(FMBH.US$ : Raymond James Upgrades to Outperform from Market Perform - PT $45
• $Lamar Advertising Co(LAMR.US$ : Citigroup Up...
• $Allegiance(ABTX.US$ : Raymond James Upgrades to Outperform from Market Perform - PT $43
• $Bunge(BG.US$: JPMorgan Upgrades to Overweight from Neutral - PT $106 (from $130)
• $Cerence(CRNC.US$ : RBC Capital Upgrades to Sector Perform from Underperform - PT $27 (from $28)
• $First Mid Bancshares(FMBH.US$ : Raymond James Upgrades to Outperform from Market Perform - PT $45
• $Lamar Advertising Co(LAMR.US$ : Citigroup Up...
11
Gainers:
• $Cogent Biosciences(COGT.US$ +7.9% (announces positive initial clinical data from ongoing phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis)
• $Univar Solutions(UNVR.US$ +7.2% (expands distribution partnership with BASF)
• $Vail Resorts(MTN.US$ +6% (In reaction to earnings/guidance)
• $BeiGene(BGNE.US$ +5.4% (highlights growing portfolio and pipeline targeting hematologic mali...
• $Cogent Biosciences(COGT.US$ +7.9% (announces positive initial clinical data from ongoing phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis)
• $Univar Solutions(UNVR.US$ +7.2% (expands distribution partnership with BASF)
• $Vail Resorts(MTN.US$ +6% (In reaction to earnings/guidance)
• $BeiGene(BGNE.US$ +5.4% (highlights growing portfolio and pipeline targeting hematologic mali...
18
7
Upgrades
• $CME Group(CME.US$ : Atlantic Equities Upgrades to Overweight from Neutral - PT $235
• $Spirit Airlines(SAVE.US$ : JPMorgan Upgrades to Overweight from Neutral - PT $30 (from $24)
• $SciPlay(SCPL.US$ : Wedbush Upgrades to Outperform from Neutral - PT $17 (from $14.50)
Downgrades
• $Bilibili(BILI.US$ : ICBC Downgrades to Neutral from Outperform - PT $26.20
• $Blueprint Medicines(BPMC.US$ : Citigroup Downgrades to Se...
• $CME Group(CME.US$ : Atlantic Equities Upgrades to Overweight from Neutral - PT $235
• $Spirit Airlines(SAVE.US$ : JPMorgan Upgrades to Overweight from Neutral - PT $30 (from $24)
• $SciPlay(SCPL.US$ : Wedbush Upgrades to Outperform from Neutral - PT $17 (from $14.50)
Downgrades
• $Bilibili(BILI.US$ : ICBC Downgrades to Neutral from Outperform - PT $26.20
• $Blueprint Medicines(BPMC.US$ : Citigroup Downgrades to Se...
19
Read more